Immunocore Holdings plc (IMCR)

58.46 +0.46 (+0.79%) At close: 04:00PM EDT

Immunocore Holdings plc

92 Park Drive
Milton Park
Abingdon OX14 4RY
United Kingdom
44 12 3543 8600
https://www.immunocore.com

Sector(s): Healthcare
Industry: Biotechnology
Full-time employees: 497

Key executives

Name	Title	Pay	Exercised	Year born
Dr. Bahija Jallal Ph.D.	CEO & Executive Director	1.38M	9.72M	1961
Mr. Brian R. Di Donato M.B.A.	CFO & Head of Strategy	654.46k	19.48M	1967
Ms. Tina St. Leger	Chief Human Resources Officer	509.12k	790.91k	1968
Dr. David Berman M.D., Ph.D.	Head of Research & Development	796.62k	17.1M	1971
Mr. John Trainer M.B.A.	SVP & Chief Operating Officer	N/A	N/A	1974
Mr. John Goll III	SVP, Finance & Chief Accounting Officer	N/A	N/A	N/A
Ms. Annelise Vuidepot Ph.D.	CTO and Head of Pipeline & Platform Research	N/A	N/A	N/A
Mr. Sean D. Buckley	VP & Chief Information Officer	N/A	N/A	1983
Clayton Robertson	Head of Investor Relations	N/A	N/A	N/A
Ms. Lily Margaret Hepworth	General Counsel & Company Secretary	N/A	N/A	N/A

Amounts are as of 31 December 2023, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Immunocore Holdings plc, a commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases. The company offers KIMMTRAK for the treatment of patients with unresectable or metastatic uveal melanoma. It also develops other programs for oncology, including tebentafusp that is in Phase 2/3 clinical trial to treat advanced cutaneous melanoma. In addition, the company's product pipeline comprises IMC-F106C, which is in a Phase 3 clinical trial to treat first line advanced cutaneous melanoma; and in a Phase 1/2 clinical trial in multiple tumor types, such as platinum resistant ovarian, non-small cell lung, and endometrial carcinoma. Further, it develops IMC-R117C, which is in phase 1 clinical trial to treat colorectal and gastrointestinal cancers; IMC-M113V, which is in phase 1 clinical trial to treat human immunosuppression virus; IMC-I109V, which is in a Phase I clinical trial in patients with chronic hepatitis B virus; IMC-T119C, which is in preclinical trial for multiple solid tumor cancers; IMC-P115C, which is in preclinical trial to treat multiple solid tumor cancers; and IMC-S118AI to treat type 1 diabetes and is in preclinical trial. Immunocore Holdings plc was founded in 1999 and is headquartered in Abingdon, the United Kingdom.

Corporate governance

Immunocore Holdings plc’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.